Brief: Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026
07/04/2026 22:59
April 7 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O: SUPERNUS PHARMACEUTICALS INC - ENTERS ASSET PURCHASE AGREEMENT WITH NAVITOR ON APRIL 1, 2026 - SEC FILING SUPERNUS PHARMACEUTICALS INC - TO BUY ASSETS RELATED TO NV-5138 OR SPN-820 INCLUDING IP AND INVENTORY - SEC FILING SUPERNUS PHARMACEUTICALS INC - PURCHASE PRICE INCLUDES PHASE 2B STUDY AND MILESTONE PAYMENTS UP TO $350 MILLION - SEC FILING SUPERNUS PHARMACEUTICALS INC - AGREEMENT INCLUDES FIVE-YEAR NON-COMPETE AND NON-SOLICITATION COVENANT - SEC FILING Source text: [ID:n0001104659-26-040497] Further company coverage: SUPN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing